SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-19-062181
Filing Date
2019-11-12
Accepted
2019-11-12 09:01:41
Documents
67
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a19-17579_110q.htm 10-Q 911986
2 EX-31.1 a19-17579_1ex31d1.htm EX-31.1 12687
3 EX-31.2 a19-17579_1ex31d2.htm EX-31.2 12669
4 EX-32.1 a19-17579_1ex32d1.htm EX-32.1 10119
  Complete submission text file 0001104659-19-062181.txt   5791161

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20190930.xml EX-101.INS 1560570
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cldx-20190930.xsd EX-101.SCH 35596
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cldx-20190930_cal.xml EX-101.CAL 54296
8 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cldx-20190930_lab.xml EX-101.LAB 393090
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cldx-20190930_pre.xml EX-101.PRE 293687
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cldx-20190930_def.xml EX-101.DEF 147117
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 191206476
SIC: 2835 In Vitro & In Vivo Diagnostic Substances